Journal Mobile Options
Table of Contents
Vol. 84, No. 3-4, 1999
Issue release date: 1999
Cytogenet Cell Genet 84:230–232 (1999)
(DOI:10.1159/000015265)

The structural organization of the human aldehyde reductase gene, AKR1A1, and mapping to chromosome 1p33→p32

Fujii J. · Hamaoka R. · Matsumoto A. · Fujii T. · Yamaguchi Y. · Egashira M. · Miyoshi O. · Niikawa N. · Taniguchi N.
aDepartment of Biochemistry, Osaka University Medical School, Osaka, and Departments of bHuman Genetics and cOrthopaedics, Nagasaki University School of Medicine, Nagasaki (Japan)

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Abstract.

Genomic DNA encoding for human aldehyde reductase (AKR1A1), a member of the aldo-keto reductase superfamily, was isolated and characterized. The genomic DNA is approximately 16 kb in length and contains eight exons which encode the entire coding region and the 3′-untranslated sequences. AKR1A1 was localized on chromosome 1p33→p32 by fluorescence in situ hybridization.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bateman JB, Kojis T, Heinmann C, Klisak I, Diep A, Carper D, Nishimura C, Mohandas T, Sparkes RS: Mapping of aldose reductase gene sequences to human chromosomes 1, 3, 7, 9, 11, and 13. Genomics 17:560–565 (1993).
  2. Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily. J biol Chem 264:9547–9551 (1989).
  3. Brown L, Hedge PJ, Markham AF, Graham A: A human aldehyde dehydrogenase (aldose reductase) pseudogene: nucleotide sequence analysis and assignment to chromosome 3. Genomics 13:465–468 (1992).

    External Resources

  4. Canuto RA, Ferro M, Muzio G, Bassi AM, Leonarduzzi G, Maggiora M, Adamo D, Poli G, Lindahl R: Role of aldehyde metabolizing enzymes in mediating effects of aldehyde products of lipid peroxidation in liver cells. Carcinogenesis 15:1359–1364 (1994).

    External Resources

  5. Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF: Structure of the human aldose reductase gene. J biol Chem 266:6872–6877 (1991a).
  6. Graham A, Heath P, Morten JEN, Markham AF: The human aldose reductase gene maps to chromosome region 7q35. Hum Genet 86:509–514 (1991b).
  7. Jez JM, Flynn TG, Penning TM: A nomenclature system for the aldo-keto reductase superfamily. Adv exp Med Biol 414:579–600 (1997).
  8. Kador PF, Robinson Jr WG, Kinoshita JH: The pharmacology of aldose reductase inhibitors. A Rev Pharmacol Toxicol 25:691–714 (1985).
  9. Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana N, Lyons C, Flynn TG: Cloning and expression of human aldose reductase. J biol Chem 265:9788–979 (1990).

    External Resources

  10. Ohta T, Thoma T, Soejima H, Fukushima Y, Nagai T, Yoshiura K, Jinno Y, Niikawa N: The origin of cytologically unidentifiable chromosome abnormalities: six cases ascertained by targeted chromosome-band painting. Hum Genet 92:1–5 (1993).

    External Resources

  11. Takahashi M, Fujii J, Miyoshi E, Hoshi A, Taniguchi N: Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication of cytotoxic aldehydes. Int J Cancer 62:749–754 (1995a).
  12. Takahashi M, Fujii J, Teshima T, Suzuki K, Shiba T, Taniguchi N: Identity of a major 3-deoxyglucosone-reducing enzyme with aldehyde reductase in rat liver established by amino acid sequencing and cDNA expression. Gene 127:249–253 (1993).

    External Resources

  13. Takahashi M, Hoshi A, Fujii J, Miyoshi E, Kasahara T, Suzuki K, Aozasa K, Taniguchi N: Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. Jpn J Cancer Res 87:337–341 (1996).

    External Resources

  14. Takahashi M, Lu Y, Myint T, Fujii J, Wada Y, Taniguchi N: In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites. Biochemistry 34:1433–1438 (1995b).


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00